

ForPatients

by Roche

Relapsing-Remitting Multiple Sclerosis (RRMS)

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Trial Status
Completed

Trial Runs In
18 Countries

Trial Identifier
NCT00676715
2007-006338-32,WA21493
ACT4422g

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).

Genentech, Inc.
Sponsor

Phase 2
Phase

NCT00676715 2007-006338-32,WA21493 ACT4422g
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years & <= 55 Years

Healthy Volunteers
No
